The East Asia Health Tech 200 is HolonIQ’s annual list of the most promising startups from across digital health, biotech, medtech and other areas where entrepreneurs are driving healthcare innovation.
East Asia’s healthcare startup community is dominated by China and subsequently the East Asia Health Tech 200 reflects the strength of the Chinese economy, with clinical research and health hardware the major contributors to the 2022 list. Compared to other areas of the continent, the companies in the East Asia cohort are predominantly focused on B2B opportunities and this is reflected in the high number of startups creating healthcare products as opposed to delivering services. While there is a growing digital health community in the region - with diagnostic technologies a particular strength - there is a strong focus on novel IP, particularly in medical devices and biotechnology.
East Asia’s strength in Biotech, Biopharma, Genomics and Medical Devices is clearly evident in the East Asia Health Tech 200.
The 2022 East Asia Health Tech 200 is mapped to the HolonIQ Global Healthcare Landscape, an open-source taxonomy for the future of health and wellness. By categorizing the 2022 cohort against the Taxonomy we are able to gain a clearer picture of the East Asia health startup world. Once we look closer at the make-up of these clusters, it is evident where the funding and entrepreneurial activity is focused and which organizations have been active in raising capital in the market, in particular: Sironax (Clinical-stage biotechnology company); Ubie (Provides AI-based healthcare products); Shanghai Bao (Biopharmaceutical company); SiBionics (implantable medical devices) and Zhenge Biotech (drug production).